Swiss company Lonza has received a three-year contract from the NIH worth $7 million. Lonza will provide the NIH's Center for Regenerative Medicine with treatment-grade induced pluripotent stem cells for research.
NIH awards stem cell contract to Lonza
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|